top of page
645950870579342784.jpg

Doctors need to know the best treatments for severe brain swelling after head injuries in order to improve outcomes for patients. The two main drugs that are currently used to treat brain swelling are mannitol (a sugary solution) and hypertonic saline (a strong salt solution). Both of these drugs work by reducing brain swelling which helps to reduce pressure on the brain. Currently, it is not known which drug is the most effective treatment. Both drugs have un-desirable side effects (mannitol can cause kidney failure and hypertonic saline causes an imbalance of salts in the blood). To deliver the best treatment we need to know which is most the safest and most effective.

​

This study is designed to work out which is the most effective treatment for brain swelling. 468 patients who have sustained a severe injury to the brain and require treatment in intensive care will take part in the study. Half the patients will receive the sugary solution and half will receive the salty solution. Which of the two treatments they receive will be decided randomly using a computer programme.

​

The study will compare how effective the different drugs are at reducing the pressure on the brain. It will also assess which is better at helping the patient to recover and what the side effects of treatment were. The study team will keep in contact with participants for 12 months after the study to check on how well they have recovered over time. Researchers will also calculate how much each treatment costs and compare this to how beneficial they were.

The study will take place in neurosurgical intensive care units across the UK and is expected to finish in February 2026.

INCLUSION CRITERIA

  1. Adult patients <16

  2. Admitted to ICU with traumatic brain injury

  3. ICP>20 for 5 minutes or more, despite stage 1 procedures

  4. <10 days since injury

  5. Abnormal CT scan, consistent with traumatic brain injury

EXCLUSION CRITERIA

1) Devastating brain injury with withdrawal of treatment anticipated in the next 24 hours
2) Pregnancy
3) Severe hypernatraemia (serum Na > 155 mmol/L)
4) 2 or more prior doses of hyperosmolar therapy given on ICU



 

Study Information

Primary outcome measure: Extended Glasgow Outcome Score (GOS-E) measured at 6 months after randomisation

Target recruitment: 468 patients

NB Patients can have received hyperosmolar therapy prior to ICU admission

Go Back.JPG

© 2035 by Dr Phil Hopkins

bottom of page